GeneDx Holdings Ownership

WGS Stock   57.79  0.40  0.69%   
GeneDx Holdings Corp has a total of 26.94 Million outstanding shares. Over half of GeneDx Holdings' outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as GeneDx Holdings in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of GeneDx Holdings, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividend Paid And Capex Coverage Ratio is likely to gain to -29.97 in 2024. Common Stock Shares Outstanding is likely to gain to about 25.5 M in 2024, despite the fact that Net Loss is likely to grow to (469.4 M).
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in GeneDx Holdings Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

GeneDx Stock Ownership Analysis

About 25.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 4.38. GeneDx Holdings Corp had not issued any dividends in recent years. The entity had 1:33 split on the 4th of May 2023. For more information please call Katherine Stueland at 888 729 1206 or visit https://www.genedx.com.
Besides selling stocks to institutional investors, GeneDx Holdings also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different GeneDx Holdings' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align GeneDx Holdings' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

GeneDx Holdings Quarterly Liabilities And Stockholders Equity

389.1 Million

GeneDx Holdings Insider Trades History

About 25.0% of GeneDx Holdings Corp are currently held by insiders. Unlike GeneDx Holdings' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against GeneDx Holdings' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of GeneDx Holdings' insider trades
 
Covid

GeneDx Holdings Corp Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific GeneDx Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on GeneDx Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases GeneDx Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Ruch Joshua six days ago
Disposition of 130 shares by Ruch Joshua of GeneDx Holdings subject to Rule 16b-3
 
Kevin Feeley over a month ago
Disposition of 2635 shares by Kevin Feeley of GeneDx Holdings at 37.59 subject to Rule 16b-3
 
Katherine Stueland over a month ago
Disposition of 6546 shares by Katherine Stueland of GeneDx Holdings subject to Rule 16b-3
 
Katherine Stueland over a month ago
Disposition of 6546 shares by Katherine Stueland of GeneDx Holdings subject to Rule 16b-3
 
Kevin Feeley over a month ago
Disposition of 262 shares by Kevin Feeley of GeneDx Holdings at 31.7096 subject to Rule 16b-3
 
Kevin Feeley over a month ago
Disposition of 717 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3
 
Opko Health, Inc. over two months ago
Disposition of 50000 shares by Opko Health, Inc. of GeneDx Holdings at 34.4904 subject to Rule 16b-3
 
Opko Health, Inc. over two months ago
Disposition of 50000 shares by Opko Health, Inc. of GeneDx Holdings at 34.297 subject to Rule 16b-3
 
Opko Health, Inc. over two months ago
Disposition of 24987 shares by Opko Health, Inc. of GeneDx Holdings at 34.7582 subject to Rule 16b-3
 
Opko Health, Inc. over two months ago
Disposition of 100000 shares by Opko Health, Inc. of GeneDx Holdings at 31.8238 subject to Rule 16b-3
 
Opko Health, Inc. over two months ago
Disposition of 12994 shares by Opko Health, Inc. of GeneDx Holdings at 29.3541 subject to Rule 16b-3
 
Kevin Feeley over two months ago
Disposition of 753 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3

GeneDx Holdings Corporate Filings

F4
17th of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
18th of September 2024
An amendment to the original Schedule 13D filing
ViewVerify
8K
30th of July 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.